98 Like Ang II, Ang III displays similar affinity for AT 1 and AT 2 receptors (Figure 2), 99 but it is more sensitive to aminopeptidase N
On paper, semaglutide wins the head-to-head comparison for monotherapy weight loss
Investigating the same primary endpoint, TRANSCEND-T2D-2 (NCT06260722) will compare retatrutide to semaglutide in people with inadequately controlled T2D (treated with oral glucose-lowering treatments) over 26 months
Minimize bloating, abdominal discomfort, irritability, , and lower back pain
Consider that the overall cost of peptide therapy is more manageable when planned as a complete protocol rather than incremental purchases
R-lipoic acid (R-fraction): included alongside glutathione as part of the supportive nutrient blend